These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 24950467)

  • 1. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology.
    Rosfjord E; Lucas J; Li G; Gerber HP
    Biochem Pharmacol; 2014 Sep; 91(2):135-43. PubMed ID: 24950467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian and cervical cancer patient derived xenografts: The past, present, and future.
    Boone JD; Dobbin ZC; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2015 Aug; 138(2):486-91. PubMed ID: 26026736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New models for cancer research: human cancer stem cell xenografts.
    Baiocchi M; Biffoni M; Ricci-Vitiani L; Pilozzi E; De Maria R
    Curr Opin Pharmacol; 2010 Aug; 10(4):380-4. PubMed ID: 20561817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
    Ruggeri BA; Camp F; Miknyoczki S
    Biochem Pharmacol; 2014 Jan; 87(1):150-61. PubMed ID: 23817077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?
    Damia G; D'Incalci M
    Eur J Cancer; 2009 Nov; 45(16):2768-81. PubMed ID: 19762228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse tumour models to guide drug development and identify resistance mechanisms.
    Das Thakur M; Pryer NK; Singh M
    J Pathol; 2014 Jan; 232(2):103-11. PubMed ID: 24122209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The challenge of selecting the 'right' in vivo oncology pharmacology model.
    Firestone B
    Curr Opin Pharmacol; 2010 Aug; 10(4):391-6. PubMed ID: 20634135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
    Hammer S; Sommer A; Fichtner I; Becker M; Rolff J; Merk J; Klar U; Hoffmann J
    Clin Cancer Res; 2010 Mar; 16(5):1452-65. PubMed ID: 20179216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.
    Sémiond D; Sidhu SS; Bissery MC; Vrignaud P
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):515-28. PubMed ID: 23820961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived xenografts as tools in pharmaceutical development.
    Izumchenko E; Meir J; Bedi A; Wysocki PT; Hoque MO; Sidransky D
    Clin Pharmacol Ther; 2016 Jun; 99(6):612-21. PubMed ID: 26874468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors.
    Cho YB; Hong HK; Choi YL; Oh E; Joo KM; Jin J; Nam DH; Ko YH; Lee WY
    J Surg Res; 2014 Apr; 187(2):502-9. PubMed ID: 24332554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.
    Kumar S; Mokhtari RB; Yeger H; Baruchel S
    Expert Opin Drug Discov; 2012 Nov; 7(11):1093-106. PubMed ID: 22998522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Derived Xenograft: An Adjuvant Technology for the Treatment of Metastatic Disease.
    Bousquet G; Janin A
    Pathobiology; 2016; 83(4):170-6. PubMed ID: 27010922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies.
    Rowinsky EK
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4220s-4226s. PubMed ID: 15217962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of patient-derived tumor xenografts in cancer treatment.
    Sia D; Moeini A; Labgaa I; Villanueva A
    Pharmacogenomics; 2015; 16(14):1671-83. PubMed ID: 26402657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.
    Wong H; Choo EF; Alicke B; Ding X; La H; McNamara E; Theil FP; Tibbitts J; Friedman LS; Hop CE; Gould SE
    Clin Cancer Res; 2012 Jul; 18(14):3846-55. PubMed ID: 22648270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug Development Based on Intracellular Pharmacokinetic Analysis of Molecular Target Drug in Mice Bearing Patient-derived Xenograft Model].
    Hamada A
    Yakugaku Zasshi; 2020; 140(5):641-648. PubMed ID: 32378664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived xenograft models of breast cancer and their predictive power.
    Whittle JR; Lewis MT; Lindeman GJ; Visvader JE
    Breast Cancer Res; 2015 Feb; 17(1):17. PubMed ID: 25849559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the active doses in humans from animal studies: a novel approach in oncology.
    Rocchetti M; Simeoni M; Pesenti E; De Nicolao G; Poggesi I
    Eur J Cancer; 2007 Aug; 43(12):1862-8. PubMed ID: 17604156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.
    Kawaguchi T; Foster BA; Young J; Takabe K
    J Mammary Gland Biol Neoplasia; 2017 Jun; 22(2):131-139. PubMed ID: 28451789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.